Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) #Chemicals #Banking #Biotechnology #FinancialServices #InvestmentBanking #NASDAQ #Investing

The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90).The Company to Expand the Study into Additional Trial Sites in EuropePhiladelphia, Pennsylvania--(Newsfile Corp. - April 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that Institutional Review Board (IRB) has approved the increase in number of patients from sixty (60) to Ninety (90). The phase 2 clinical study (SKNJCT-003) which is...


http://dlvr.it/TKH8QT

Comments

Popular posts from this blog

SEC Investor Advisory Committee to Discuss Exempt Offerings and Accredited Investors at September 21 Meeting #Banking #FinancialServices

Cleantek Industries Inc. Announces a Twelve-Month Extension of Credit Facility #CTEK.CA #CTEK.V #GLKFF #Investing #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Technology

International Property Alerts: Global Property Exhibition Singapore 2025 Highlights London's Best New Developments #Advertising